Filing Details

Accession Number:
0001209191-20-008513
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-11 19:21:10
Reporting Period:
2020-02-07
Accepted Time:
2020-02-11 19:21:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557146 Malcolm Lloyd-Smith 12780 El Camino Real
San Diego CA 92130
Chief Regulatory Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-02-07 1,015 $103.28 23,200 No 4 S Direct
Common Stock Acquisiton 2020-02-10 13,042 $32.99 36,242 No 4 M Direct
Common Stock Disposition 2020-02-10 13,042 $104.56 23,200 No 4 S Direct
Common Stock Acquisiton 2020-02-10 15,927 $81.49 39,127 No 4 M Direct
Common Stock Disposition 2020-02-10 15,927 $104.56 23,200 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option Disposition 2020-02-10 13,042 $0.00 13,042 $32.99
Common Stock Non-Qualified Stock Option Disposition 2020-02-10 15,927 $0.00 15,927 $81.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-02-03 No 4 M Direct
17,596 2028-02-05 No 4 M Direct
Footnotes
  1. Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.56 to $105.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. Option granted February 3, 2015 and vested monthly over four years.
  7. Option granted February 5, 2018 and vests monthly over four years.